卵巢癌组织中线粒体融合蛋白2对初次肿瘤细胞减灭术后复发的预测价值  

The Predictive Value of Mitochondrial Fusion Protein 2 in Ovarian Cancer Tissue for Recurrence After Initial Tumor Cell Reduction Surgery

作　　者：贾颖娜 郑翠 何慧[1] 徐菁华 JIA Yingna;ZHENG Cui;HE Hui;XU Jinghua(Gynaecology and obstetrics,Suzhou Municipal Hospital,Suzhou 215000,China)

机构地区：[1]南京医科大学附属苏州医院妇产科,江苏苏州215000

出　　处：《标记免疫分析与临床》2024年第10期1907-1912,共6页Labeled Immunoassays and Clinical Medicine

基　　金：江苏省妇幼保健科研项目(编号:F202207)。

摘　　要：目的探讨卵巢癌组织中线粒体融合蛋白2(MFN2)对初次肿瘤细胞减灭术后复发的预测价值。方法收集2020年3月至2023年2月苏州市立医院收治的卵巢癌患者病例资料进行回顾性分析,全部患者均完成肿瘤细胞减灭术且获得至少2年随访结果,统计随访2年内复发率。根据研究目的,统计卵巢癌组织中MFN2表达,根据统计结果将患者分为MFN2阳性组和阴性组,比较两组肿瘤复发情况以及一般临床资料。采用Cox回归,分析卵巢癌组织中MFN2对初次肿瘤细胞减灭术后复发的影响。绘制决策曲线,评估卵巢癌组织中MFN2对初次肿瘤细胞减灭术后复发的预测价值。结果共收集3年内98例卵巢癌患者病例资料,复发时间为18.0(13.0,24.0)月,67例患者在随访24个月内相继复发,复发率为68.37%。MFN2阳性患者FIGO III期比例、肿瘤复发比例少于阴性患者,血清人附睾蛋白4(HE4)、血管内皮生长因子(VEGF)、甲胎蛋白(AFP)表达低于阴性患者,差异有统计学意义(P<0.05)。复发组FIGO III期、MFN2阴性比例高于未复发组,血清HE4、VEGF、AFP表达高于未复发组,差异有统计学意义(P<0.05)。Cox回归数据显示,血清HE4、VEGF高表达,组织中MFN2阴性是导致卵巢癌患者肿瘤细胞减灭术后2年内复发的危险因素(P<0.05)。绘制决策曲线,血清VEGF、HE4、卵巢癌组织中MFN2预测初次肿瘤细胞减灭术后复发具有良好的净获益,且联合预测曲线高于独立指标预测。结论卵巢癌患者初次肿瘤细胞减灭术后2年内复发与组织中MFN2阴性表达有关,检测卵巢癌组织中MFN2表达有助于预测2年内复发风险。Objective To investigate the predictive value of mitochondrial fusion protein 2(MFN2)in ovarian cancer tissue on recurrence after primary tumor cell reduction surgery.Methods A retrospective analysis was conducted for case data of ovarian cancer patients admitted to Suzhou Municipal Hospital from March,2020 to February,2023.All patients completed tumor cell reduction surgery and at least 2 years of follow-up results were obtained.The recurrence rate within 2 years of follow-up was calculated.According to the research goal,the expression of MFN2 in ovarian cancer tissue was measured.Patients were divided into MFN2 positive and negative groups based on the statistical analysis results,and the tumor recurrence and general clinical data were compared between the two groups.Cox regression was applied to evaluate the effect of MFN2 in ovarian cancer tissue on recurrence after primary tumor cell reduction surgery.A decision curve was drawn to evaluate the predictive value of MFN2 in ovarian cancer for recurrence after primary tumor cell reduction.Results This study collected data from 98 ovarian cancer patients over a period of 3 years,with a recurrence time of 18.0(13.0,24.0)months.67 patients recurred within 24 months of follow-up,with a recurrence rate of 68.37%.The proportion of FIGO stage III and tumor recurrence in MFN2 positive patients were lower than those in negative patients,while expressions of human epididymal protein 4(HE4),vascular endothelial growth factor(VEGF)and alpha-fetoprotein(AFP)in serum were significantly lower than that in negative patients(P<0.05).Cox regression results showed that the high expressions of HE4 and VEGF in serum and the negative expression of MFN2 in tissues were risk factors for recurrence of ovarian cancer patients within 2 years after tumor cell reduction surgery(P<0.05).The decision curve showed that serum VEGF,HE4,and MFN2 in ovarian cancer tissue had a good net benefit in predicting recurrence after primary tumor cell reduction,and the combined prediction curve was higher

关 键 词：卵巢癌 肿瘤细胞减灭术 线粒体融合蛋白2 复发 

分 类 号：R737.31[医药卫生—肿瘤]